Skip to main content

AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T market

Submitted by admin on
snippet

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline.

Source
Fierce Biotech
Headline
https://www.fiercebiotech.com/biotech/abbvie-reels-capstan-21b-buyout-charting-…
News Tags
AbbVie
M&A
Capstan Therapeutics
CAR-T

Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise

Submitted by admin on
snippet

Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring its first prospect into clinical testing. 

Source
BioPharma Dive
Headline
Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise
News Tags
Capstan Therapeutics
cell therapy
funding
Subscribe to Capstan Therapeutics